vesnarinone has been researched along with pyrazines in 191 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 39 (20.42) | 18.7374 |
| 1990's | 112 (58.64) | 18.2507 |
| 2000's | 36 (18.85) | 29.6817 |
| 2010's | 4 (2.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hayashida, W; Kawai, C; Kumada, T | 1 |
| Wu, C; Wu, S | 1 |
| Yin, GK; Zhan, XC | 1 |
| Du, J; Yang, Z | 1 |
| Futaki, S; Goto, Y; Hata, K; Kawaguchi, O; Nishioka, T; Saeki, A; Suga, H; Takasago, T | 1 |
| Baughman, KL; Feldman, AM; Strobeck, JE | 1 |
| Becker, EW; Berg, PA; Busch, FW; Owsianowski, M; Tillmann, A | 1 |
| Lan, T; Wang, Y; Yang, Z; Zha, Z; Zhou, Z | 1 |
| Hu, H; Tao, D; Xing, Y; Yang, Z; Zheng, X | 1 |
| Luo, F; Wu, C; Zhang, Q; Zhou, Z | 1 |
| Alex, S; Braverman, LE; Fang, SL; Lueprasitsakul, W | 1 |
| Baughman, KL; Becker, LC; Feldman, AM; Gottlieb, SH; Lee, WK; Strobeck, JE; Weiss, JL | 1 |
| Fukuda, K; Handa, S; Kawamura, Y; Nakamura, Y; Ogawa, S | 2 |
| Lan, T; Yang, Z; Zha, Z; Zhou, Z | 1 |
| Lathrop, DA; Schwartz, A | 2 |
| Blinks, JR; Endoh, M; Taira, N; Yanagisawa, T | 1 |
| Iijima, T; Taira, N | 1 |
| Ishii, K; Taira, N; Yanagisawa, T | 1 |
| Brown, AM; Imoto, Y; Schwartz, A; Yatani, A | 1 |
| Asanoi, H; Ishizaka, S; Iuchi, K; Kameyama, T; Sasayama, S | 1 |
| Lathrop, DA; Schwartz, A; Varró, A | 1 |
| Beavo, JA; Harrison, SA; Lathrop, DA; Rapundalo, ST; Schwartz, A | 1 |
| Inoue, K; Ito, N; Kinoshita, H; Maehara, K; Maruyama, Y; San-ei, ND; Shimizu, Y; Takahashi, T; Takishima, T | 1 |
| Baughman, KL; Becker, LC; Feldman, AM; Llewellyn, MP | 1 |
| Hori, M; Inoue, M; Kodama, K; Kusukawa, R; Nonogi, H; Sakurai, T; Sasayama, S; Sugimoto, T; Takishima, T; Yasuda, H | 1 |
| Cohn, JN; Kubo, SH; Rector, TS; Strobeck, JE | 1 |
| Ishizaki, T; Ohnishi, A | 1 |
| Miyamoto, G; Sasabe, H; Shimizu, T; Tominaga, M; Tominaga, N; Uegaki, N | 1 |
| Futaki, S; Nozawa, T; Suga, H; Tanaka, N; Yasumura, Y | 1 |
| Hamanaka, Y; Hori, M; Inoue, M; Kimura, Y; Kodama, K; Masuyama, T; Mishima, M; Nanto, S | 1 |
| Asanoi, H; Iuchi, K; Kameyama, T; Sasayama, S | 1 |
| Hori, M; Inoue, M; Ito, H; Iwai, K; Kamada, T; Kitabatake, A; Kitakaze, M; Koretsune, Y; Tamai, J | 1 |
| Asanoi, H; Hori, M; Inoue, M; Kawai, C; Kodama, K; Sakurai, T; Sasayama, S | 1 |
| Hashimoto, K; Mitsuhashi, H | 1 |
| Hori, M; Inoue, M; Iwai, K; Iwakura, K; Kamada, T; Kitakaze, M; Koretsune, Y; Tamai, J | 1 |
| Higashino, Y; Hori, M; Inoue, M; Kamada, T; Kim, BH; Kodama, K; Matsubara, N; Naka, M; Nanto, S; Tsuneoka, Y | 1 |
| Miyamoto, G; Odomi, M; Sasabe, H; Shimizu, T | 1 |
| Endoh, M; Taira, N; Yanagisawa, T | 1 |
| Hosokawa, T; Kojima, M; Mori, T; Yabuuchi, Y; Yamashita, S | 1 |
| Endoh, M; Iijima, T; Kawada, M; Maruyama, M; Morita, T; Satoh, K; Taira, N; Wada, Y; Yamashita, S; Yanagisawa, T | 1 |
| Ando, H; Kobayashi-Ando, S; Takeya, K; Yajima, M | 1 |
| Nakagawa, K; Ogawa, H; Tominaga, M; Yabuuchi, Y; Yamashita, S; Yo, E | 1 |
| Nakagawa, K; Niimi, K; Osumi, T; Shimizu, T | 1 |
| Abe, H; Fukunami, M; Hori, M; Inoue, M; Ishida, Y; Kitakaze, M; Nakajima, S | 1 |
| Grupp, G; Grupp, IL; Newman, G; Schwartz, A | 1 |
| Hashimoto, K; Satoh, H | 1 |
| Endo, M | 1 |
| Hosakawa, T; Lee, SW; Matlib, MA; Schwartz, A; Wallick, ET; Wang, T; Whitmer, KR | 1 |
| Hashimoto, K; Mori, T; Yabuuchi, Y; Yamashita, S | 1 |
| Miyamoto, G; Sasabe, H | 1 |
| Bertolet, BD; Pepine, CJ; White, BG | 1 |
| Katoh, I; Kyushiki, H; Sakamoto, Y; Yoshinaka, Y | 1 |
| Lachin, JM; Lan, KK; Rosenberger, WF | 1 |
| Hattori, S; Hattori, Y; Kasai, K; Shimoda, S; So, S | 1 |
| Gelfand, EW; Kumakura, T; Takase, K; Terada, N | 1 |
| Liu, S; Yin, G; Zhan, X | 1 |
| Ando, H; Ando, S; Nomura, H; Takeya, K; Yajima, M | 1 |
| Adachi, M; Bando, T; Harada, K; Kawai, K; Nakai, S; Nakashiro, K; Sato, M; Shirakami, T; Yoshida, H | 1 |
| Moore, CK; O'Connell, JB; Waterer, HC | 1 |
| Gheorghiade, M; Han, D; Tauke, J | 1 |
| Han, W; Qin, Y; Yang, Z; Zhang, Z; Zhou, S | 1 |
| Uetrecht, JP; Whitfield, D; Zahid, N | 1 |
| Matsui, S; Matsumori, A; Sasayama, S | 1 |
| Matoba, Y; Matsui, S; Matsumori, A; Sasayama, S; Uchida, A | 1 |
| Matsui, S; Matsumori, A; Sasayama, S; Shioi, T; Yamada, T | 1 |
| Feldman, AM; Strobeck, JE | 1 |
| Miyoshi, Y; Nakaya, Y; Nomura, M; Saito, K; Shono, M; Wakatsuki, T | 1 |
| Enokihara, H; Furusawa, S; Hayashida, T; Saito, K; Shishido, H; Waga, K; Yamato, R | 1 |
| Chen, IS; Ikeda, M; Kitajima, I; Maruyama, I; Maruyama, Y; Nakai, S; Nakajima, T; Osame, M; Yabu-uchi, Y; Zhao, JQ | 1 |
| Lathrop, DA; Nánási, PP; Schwartz, A; Varró, A | 1 |
| Lan, T; Lin, D | 1 |
| Matsui, S; Matsumori, A; Sasayama, S; Shioi, T | 1 |
| Swedberg, K; Wedel, H | 1 |
| Neely, D | 1 |
| Grupp, G; Grupp, I; Schwartz, A | 1 |
| Ito, M; Konishi, T; Kozeki, H; Masuoka, H; Nakano, T; Sugioka, M; Tanaka, T | 1 |
| Ito, M; Itoh, H; Konishi, T; Kusagawa, M; Nakano, T; Shimomura, A; Suga, T | 1 |
| Bain, RP; Bristow, MR; Carson, PE; Feldman, AM; Gilbert, EM; Hendrix, GH; Parmley, WW; Pepine, CJ; Powers, ER; Strobeck, JE | 1 |
| Packer, M | 1 |
| Banasik, M; Kido, T; Nakajima, S; Ueda, K; Yook, HY | 1 |
| Adachi, M; Honma, Y; Hozumi, M; Nakai, S; Okabe-Kado, J; Sato, S; Tomoyasu, S; Tsuruoka, N | 1 |
| Matsumori, A; Sasayama, S | 4 |
| Matsumori, A; Sasayama, S; Sato, Y | 1 |
| Bain, RP; Lachin, JM; Rosenberger, WF | 1 |
| McCloskey, TW; Oyaizu, N; Pahwa, S; Than, S | 1 |
| Asanoi, H; Inoue, H | 1 |
| Chen, G | 1 |
| Lan, T; Li, H; Zeng, X; Zhang, Y | 1 |
| Asanoi, H; Furusawa, S; Ohashi, Y | 1 |
| Furukawa, Y; Iwasaki, A; Matsumori, A; Nakamura, T; Okada, I; Ono, K; Sasayama, S; Shioi, T | 1 |
| Becker, LC; Feldman, AM; Kasper, EK; Kass, DA; Van Anden, E; White, WB | 1 |
| Matsumori, A | 1 |
| Cheng, J; Kamiya, K; Kodama, I; Lee, JK; Suzuki, R; Toyama, J | 2 |
| DiSesa, VJ; Fyfe, BS; Goldstein, C; Mohiuddin, M; Momeni, R; Shen, Z; Whitman, GJ; Yokoyama, H | 1 |
| Matsumori, A; Nose, Y; Ono, K; Sasayama, S; Sato, Y; Shioi, T | 1 |
| Furukawa, Y; Hirozane, T; Matoba, Y; Matsui, S; Matsumori, A; Sasayama, S | 1 |
| Kurabayashi, M; Yamaoki, K; Yazaki, Y | 1 |
| Adachi, M; Gohda, H; Harada, K; Ikeda, Y; Kawamata, H; Kinoshita, M; Nakashiro, K; Nishida, T; Ono, K; Sato, M; Yoshida, H | 1 |
| Kurokawa, H; Nagata, K; Nara, N; Tanikawa, S; Tohda, S; Tomiyama, J | 1 |
| Sasayama, S | 5 |
| Marsh, JD; Vander Heide, RS | 1 |
| Funaya, H; Hori, M; Kitakaze, M; Minamino, T; Mori, H; Node, K; Shinozaki, Y | 1 |
| Aizawa, S; Handa, H; Imai, T; Kaidow, A; Nabeshima, R; Nakano, M; Sugimoto, K; Toyama, K | 1 |
| Baumann, H; Jacob, CO; Kambayashi, T; Lazarus, DD; Strassmann, G; Yato-Kioka, M | 1 |
| Hirahara, N; Minari, Y; Nio, Y; Ohmori, H; Sasaki, S; Takamura, M; Tamura, K | 1 |
| Arima, N; Arimura, K; Fujiwara, H; Hidaka, S; Kukita, T; Matsushita, K; Otsubo, H; Tanaka, H; Yamaguchi, K | 1 |
| Aizawa, S; Handa, H; Hoshi, H; Imai, T; Iwase, O; Kaido, A; Kuriyama, Y; Nabeshima, R; Nakano, M; Sugimoto, K; Tanaka, K; Toyama, K; Yaguchi, M | 1 |
| Cai, G; Han, W; Wu, Y; Yang, Z; Zhang, Z | 1 |
| Cavusoglu, E; Frishman, WH; Klapholz, M | 1 |
| Fong, M; Hori, M; Kambayashi, T; Kitakaze, M; Minamino, T; Node, K; Okuyama, Y; Terada, N; Yoshitake, M | 1 |
| Hamano, H; Hino, S; Kawamata, H; Miwa, Y; Nakashiro, K; Omotehara, F; Sato, M; Uchida, D; Yoshida, H | 1 |
| Hino, S; Kawamata, H; Nakashiro, K; Omotehara, F; Sato, M; Uchida, D; Yoshida, H | 1 |
| Nagai, H; Tanaka, H; Uno, T | 1 |
| Bramer, SL; Cowart, DT; Kisicki, J; Koneru, B; Noorisa, M | 1 |
| Bramer, S; Cowart, DC; Flockhart, DA; Girard, AF; Lang, CC; Wandel, C; Wood, AJ | 1 |
| Ikeda, U; Kurosaki, K; Maeda, Y; Shimada, K; Shimpo, M; Ueno, S | 1 |
| Lathrop, DA; Nánási, PP; Varró, A | 1 |
| Cocca-Spofford, D; Dec, GW; DiSalvo, TG; Picard, MH; Scherrer-Crosbie, M; Semigran, MJ | 1 |
| Bourge, RC; Cohn, JN; DeMets, DL; Goldstein, SO; Gottlieb, SO; Greenberg, BH; Jaski, BE; Lorell, BH; McGrew, F; White, BG | 1 |
| Stevenson, LW | 1 |
| Kato, A; Kubo, K; Matsuzaki, Y; Okita, K; Terai, S | 1 |
| Cao-Danh, H; Cowan, DB; del Nido, PJ; Friehs, I; Glynn, P; Ibrahim, AE; McGowan, FX; Poutias, D; Takeuchi, K | 1 |
| Bramer, SL; Cowart, TD; Schorno, KS; Tata, PN | 1 |
| Osaki, T; Ueta, E; Yamamoto, T; Yoneda, K | 1 |
| Borer, JS; Goldfine, SM; Herrold, EM; Ross, JS | 1 |
| Nicklas, JM; Pitt, B | 1 |
| Fujita, M; Higashino, K; Tsuchida, T | 1 |
| Sawada, M; Suzumura, A | 1 |
| Pritzker, MR | 1 |
| Alhaddad, IA | 1 |
| Sawada, M; Suzumura, A; Takayanagi, T; Tamaru, T; Yoshikawa, M | 1 |
| Endoh, M; Hino, M; Sakato, M; Sugawara, H; Yoshimura, A; Yoshioka, K | 1 |
| Honma, Y; Kanatani, Y; Yamamoto-Yamaguchi, Y | 1 |
| Hayashi, K; Ito, R; Ono, S; Tahara, E; Yokozaki, H | 1 |
| Adachi, M; Hori, T; Kawai, K; Nakai, S; Tanaka, S | 1 |
| Bergey, G; Bielekova, B; Clarence-Smith, K; Dhib-Jalbut, S; Jiang, H; Johnson, KP; Martin, R; Okazaki, H | 1 |
| Bourge, R; Carson, P; Feldman, AM; Holubkov, R; Jaski, B; Loftus, S; Soran, O; White, BG; Young, JD | 1 |
| Lachin, JM | 1 |
| Hiroe, M; Hosokawa, T; Ikeda, I; Ishiyama, S; Kasajima, T; Marumo, F; Nishikawa, T; Shimojo, T; Toyozaki, T | 1 |
| Bramer, SL; Cowart, TD; Frye, RF; Tammara, B | 1 |
| Adachi, M; Amuro, Y; Hada, T; Higashino, K; Ohkawa, T; Taguchi, T; Takahashi, M; Ueki, N | 1 |
| Aggarwal, BB; Manna, SK | 1 |
| Findlay, I; Fujita, A; Katayama, Y; Kurachi, Y; Ohe, T | 1 |
| Cohn, JN; Feldman, AM; Holubkov, R; Reis, SE; White, BG; Young, JB | 1 |
| LeJemtel, TH | 1 |
| Matsumori, A; Nunokawa, Y; Sasayama, S | 1 |
| Cowan, DB; del Nido, PJ; McGowan, FX; Munakata, M; Poutias, DN; Takeuchi, K | 1 |
| Drengler, RL; Eckhardt, SG; Felton, SA; Garner, AM; Hammond, LA; Hidalgo, M; Mallikaarjun, S; Patnaik, A; Rowinsky, EK; Siu, LL; Tammara, BK; Von Hoff, DD | 1 |
| Deswal, A; Feldman, AM; Mann, DL; Petersen, NJ; White, BG; Young, JB | 1 |
| Iwabu, A; Kumashiro, H; Kusachi, S; Murakami, T; Ninomiya, Y; Nunoyama, H; Oka, T; Sano, I; Tsuji, T; Ueta, J | 1 |
| Kamiya, K; Kodama, I; Mitcheson, JS; Sanguinetti, MC; Yasui, K | 1 |
| Deswal, A; Feldman, AM; Mann, DL; Petersen, NJ; White, BG | 1 |
| Poole-Wilson, PA; van Veldhuisen, DJ | 1 |
| Cheng, JH; Kamiya, K; Kodama, I | 1 |
| Byers, J; Harvey, W; Khalaf, W; Maina, C | 1 |
| Anderson, S; Douglas, J; Wang, C | 1 |
| Daido, N; Domae, N; Iwai, K; Kitano, T; Kondo, T; Okazaki, T; Suzuki, Y; Tashima, M; Uchiyama, T; Umehara, H; Watanabe, M | 1 |
| Fujimori, T; Hino, S; Kawamata, H; Nakashiro, K; Omotehara, F; Uchida, D | 3 |
| Ferrer, T; Navarro-Polanco, RA; Sănchez-Chapula, JA; Sanguinetti, MC | 1 |
| Bramer, SL; Sekar, KS | 1 |
| Battagliese, A; Bucciarelli Ducci, C; Celotto, A; De Luca, L; Fedele, F; Palombaro, GL; Proietti, P | 1 |
| Kurachi, Y; Suzuki, S; Tsujimae, K; Yamada, M | 1 |
| Young, JB | 1 |
| Feldman, AM | 1 |
| Bertolet, BD | 1 |
| Gardner, I; Popović, M; Uetrecht, JP; Zahid, N | 1 |
| Harada, K; Sato, M; Yoshida, H | 1 |
| Fujimori, T; Imai, Y; Kawamata, H; Tachibana, M | 1 |
| Eickhoff, JC | 1 |
| Abe, S; Hino, T; Hosokawa, T; Inage, M; Kato, S; Nakamura, H; Ogura, M; Saito, H; Sata, M; Takabatake, N; Terashita, K; Tomoike, H | 1 |
| Begum, NM; Kuribayashi, N; Miyamoto, Y; Nagai, H; Onoue, T; Tamatani, T; Tomizuka, Y; Uchida, D | 1 |
| Cas, LD; Cotter, G; Gheorghiade, M; Metra, M; Sabbah, HN; Teerlink, JR; Zacà, V | 1 |
| Aizawa, S; Ando, H; Azuma, M; Handa, H; Hiramoto, M; Hotta, K; Iizumi, Y; Imai, T; Ito, T; Kabe, Y; Nabeshima, R; Nashimoto, A; Okada, A; Sakamoto, S; Sakata-Sogawa, K; Shima, D; Suzuki, M; Tokunaga, M; Watanabe, H; Yamaguchi, Y; Yasumura, E | 1 |
| Piao, HR; Wu, Y | 1 |
| Andrei, AC; Grady, KL | 1 |
| Durdagi, S; Kayık, G; Tüzün, NŞ | 1 |
26 review(s) available for vesnarinone and pyrazines
| Article | Year |
|---|---|
[New oral drugs for the treatment of congestive heart failure].
Topics: Administration, Oral; Cardiotonic Agents; Deoxyepinephrine; Ethanolamines; Heart Failure; Humans; Phosphodiesterase Inhibitors; Piperidines; Propanolamines; Pyrazines; Quinolines; Quinolones; Vasodilator Agents; Xamoterol | 1992 |
Treatment of end stage dilated cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Cardiomyopathy, Dilated; Cardiotonic Agents; Heart Transplantation; Humans; Pyrazines; Quinolines; Vasodilator Agents | 1994 |
Reassessment of digoxin and other low-dose positive inotropes in the treatment of chronic heart failure.
Topics: Adrenergic beta-Agonists; Cardiotonic Agents; Digoxin; Double-Blind Method; Drug Evaluation; Electrophysiology; Heart Failure; Hemodynamics; Humans; Myocardial Contraction; Neurosecretory Systems; Phosphodiesterase Inhibitors; Pyrazines; Quinolines | 1994 |
Quinolinone derivatives in the management of congestive heart failure.
Topics: Animals; Cardiotonic Agents; Heart Failure; Humans; Pyrazines; Quinolines; Quinolones | 1994 |
[Role of cytokines in etiological mechanism of congestive heart failure].
Topics: Cardiotonic Agents; Cytokines; Cytotoxicity, Immunologic; Heart Failure; Humans; Killer Cells, Natural; Pyrazines; Quinolines | 1995 |
Immunomodulating agents for the management of heart failure with myocarditis and cardiomyopathy--lessons from animal experiments.
Topics: Adjuvants, Immunologic; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Cardiomyopathy, Dilated; Cardiotonic Agents; Cardiovirus Infections; Cytokines; Encephalomyocarditis virus; Heart Failure; Humans; Mice; Myocarditis; Prodrugs; Pyrazines; Quinolines; Tetrazoles; Tumor Necrosis Factor-alpha | 1995 |
Vesnarinone-induced granulocytopenia: incidence in Japan and recommendations for safety.
Topics: Adult; Agranulocytosis; Cardiotonic Agents; Humans; Incidence; Japan; Male; Product Surveillance, Postmarketing; Pyrazines; Quinolines | 1996 |
Cytokines in myocarditis and cardiomyopathies.
Topics: Animals; Cardiomyopathy, Dilated; Cardiotonic Agents; Cytokines; Heart Injuries; Hepatitis C; Humans; Mice; Mice, Mutant Strains; Myocarditis; Pyrazines; Quinolines | 1996 |
Vesnarinone: a potential cytokine inhibitor.
Topics: Adjuvants, Immunologic; Animals; Cytokines; Heart Failure; Humans; Pyrazines; Quinolines | 1996 |
Ion channel blockers in the treatment of chronic heart failure.
Topics: Amiodarone; Animals; Calcium Channel Blockers; Chronic Disease; Heart Failure; Humans; Potassium Channel Blockers; Pyrazines; Quinolines | 1996 |
[Dilated cardiomyopathy in children].
Topics: Angiotensin-Converting Enzyme Inhibitors; Cardiomyopathy, Dilated; Cardiotonic Agents; Child; Child, Preschool; Humans; Infant; Prognosis; Pyrazines; Quinolines | 1996 |
Inotropic agents in the treatment of heart failure: despair or hope?
Topics: Adrenergic beta-Agonists; Cardiotonic Agents; Cyclic AMP; Digitalis; Heart Failure; Humans; Plants, Medicinal; Plants, Toxic; Prognosis; Pyrazines; Pyridazines; Quinolines | 1997 |
Heart failure: clinical implications of recent trials.
Topics: Angiotensin-Converting Enzyme Inhibitors; Cardiotonic Agents; Diuretics; Heart Failure; Humans; Pyrazines; Quinolines | 1994 |
Worst-rank score analysis with informatively missing observations in clinical trials.
Topics: Cardiotonic Agents; Data Interpretation, Statistical; Follow-Up Studies; Heart Failure; Humans; Pyrazines; Quinolines; Randomized Controlled Trials as Topic | 1999 |
Review of a dose-dependent increase in mortality with vesnarinone among patients with severe heart failure.
Topics: Cardiotonic Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Heart Failure; Humans; Pyrazines; Quinolines; Survival Analysis | 1999 |
The underreporting of results and possible mechanisms of 'negative' drug trials in patients with chronic heart failure.
Topics: Bosentan; Cardiovascular Agents; Deoxyepinephrine; Heart Failure; Humans; Imidazoles; Mibefradil; Pyrazines; Quinolines; Sulfonamides; Xamoterol | 2001 |
Carvedilol and vesnarinone: new antiarrhythmic approach in heart failure therapy.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Calcium Channels, L-Type; Carbazoles; Cardiotonic Agents; Carvedilol; Heart Failure; Humans; Potassium Channels; Propanolamines; Pyrazines; Quinolines | 2001 |
[Inotropic agents].
Topics: Adrenergic alpha-Agonists; Animals; Cardiotonic Agents; Clinical Trials as Topic; Digitalis Glycosides; Heart Failure; Humans; Pyrazines; Pyridazines; Quinolines | 2003 |
Vesnarinone: a differentiation-inducing anti-cancer drug.
Topics: Animals; Antineoplastic Agents; Apoptosis; Humans; Mice; Neoplasms; Pyrazines; Quinolines; Repressor Proteins | 2003 |
New positive inotropic agents in the treatment of left ventricular dysfunction.
Topics: Cardiotonic Agents; Diastole; Heart Failure; Humans; Hydrazones; Milrinone; Myocardial Ischemia; Phosphodiesterase Inhibitors; Pyrazines; Pyridazines; Quinolines; Simendan; Ventricular Dysfunction, Left; Ventricular Function, Left | 2004 |
Clinical characteristics of vesnarinone.
Topics: Algorithms; Controlled Clinical Trials as Topic; Heart Failure; Humans; Multicenter Studies as Topic; Pyrazines; Quinolines; Time Factors | 2004 |
Precautions for use and adverse effects of vesnarinone: potential mechanisms and future therapies.
Topics: Animals; Clinical Trials as Topic; Death, Sudden; Heart Failure; Humans; Monitoring, Physiologic; Multicenter Studies as Topic; Neutropenia; Pyrazines; Quinolines; Quinolones | 2004 |
Optimising outcomes in end-stage heart failure: differences in therapeutic responses between diverse ethnic groups.
Topics: Asian People; Clinical Trials as Topic; Heart Failure; Humans; Pyrazines; Quinolines; Treatment Outcome; White People | 2004 |
Differentiation-inducing therapy for solid tumors.
Topics: Animals; Antineoplastic Agents; Cell Differentiation; Humans; Neoplasms; PPAR gamma; Pyrazines; Quinolines | 2006 |
Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond.
Topics: Acute Disease; Cardiotonic Agents; Digoxin; Dobutamine; Etiocholanolone; Exercise Test; Heart Failure; Hemodynamics; Hospitals, Group Practice; Humans; Hydrazones; Prognosis; Pyrazines; Pyridazines; Quinolines; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Simendan; Treatment Outcome; Urea; Vasodilator Agents | 2009 |
The progress towards the development of DHQO derivatives and related analogues with inotropic effects.
Topics: Animals; Cardiotonic Agents; Pyrazines; Quinolines; Quinolones; Rabbits; Stroke Volume; Structure-Activity Relationship | 2013 |
17 trial(s) available for vesnarinone and pyrazines
| Article | Year |
|---|---|
Oral milrinone in severe chronic heart failure.
Topics: Cardiotonic Agents; Heart Failure; Humans; Milrinone; Pyrazines; Pyridones; Quinolines | 1992 |
Usefulness of OPC-8212, a quinolinone derivative, for chronic congestive heart failure in patients with ischemic heart disease or idiopathic dilated cardiomyopathy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Cardiomyopathy, Dilated; Cardiotonic Agents; Coronary Disease; Double-Blind Method; Female; Heart Failure; Humans; Male; Middle Aged; Physical Exertion; Pyrazines; Quality of Life; Quinolines | 1991 |
A placebo-controlled, randomized, double-blind study of OPC-8212 in patients with mild chronic heart failure. OPC-8212 Multicenter Research Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Pressure; Cardiotonic Agents; Chronic Disease; Double-Blind Method; Echocardiography; Female; Heart Failure; Heart Rate; Humans; Male; Middle Aged; Pyrazines; Quality of Life; Quinolines; Severity of Illness Index | 1990 |
Sustained inotropic effects of a new cardiotonic agent. OPC-8212 in patients with chronic heart failure.
Topics: Adult; Aged; Cardiotonic Agents; Clinical Trials as Topic; Female; Heart Failure; Humans; Male; Middle Aged; Myocardial Contraction; Pyrazines; Quinolines; Stimulation, Chemical; Stroke Volume; Time Factors | 1989 |
Evaluation of a new inotropic agent, OPC-8212, in patients with dilated cardiomyopathy and heart failure.
Topics: Adult; Cardiomyopathy, Dilated; Cardiotonic Agents; Clinical Trials as Topic; Exercise Test; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Pyrazines; Quinolines; Respiratory Function Tests | 1988 |
A multicenter study of a new inotropic agent, piperanometozine (OPC-8212) in congestive heart failure: clinical improvement during short-term treatment.
Topics: Aged; Cardiotonic Agents; Female; Heart Failure; Humans; Male; Middle Aged; Pyrazines; Quinolines | 1987 |
Reassessment of digoxin and other low-dose positive inotropes in the treatment of chronic heart failure.
Topics: Adrenergic beta-Agonists; Cardiotonic Agents; Digoxin; Double-Blind Method; Drug Evaluation; Electrophysiology; Heart Failure; Hemodynamics; Humans; Myocardial Contraction; Neurosecretory Systems; Phosphodiesterase Inhibitors; Pyrazines; Quinolines | 1994 |
Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group.
Topics: Adult; Aged; Aged, 80 and over; Cardiotonic Agents; Double-Blind Method; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Morbidity; Proportional Hazards Models; Prospective Studies; Pyrazines; Quality of Life; Quinolines | 1993 |
Dose dependence of chronic positive inotropic effect of vesnarinone in patients with congestive heart failure due to idiopathic or ischemic cardiomyopathy.
Topics: Administration, Oral; Cardiomyopathies; Cardiotonic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Heart Failure; Hemodynamics; Humans; Pyrazines; Quinolines; Regression Analysis; Ventricular Function | 1996 |
Effect of increasing gastric pH with famotidine on the absorption and oral pharmacokinetics of the inotropic agent vesnarinone.
Topics: Administration, Oral; Area Under Curve; Cardiotonic Agents; Cross-Over Studies; Double-Blind Method; Drug Interactions; Famotidine; Female; Histamine H2 Antagonists; Humans; Hydrogen-Ion Concentration; Intestinal Absorption; Male; Metabolic Clearance Rate; Pyrazines; Quinolines | 1998 |
Effect of CYP3A inhibition on vesnarinone metabolism in humans.
Topics: Administration, Oral; Adolescent; Adult; Anti-Bacterial Agents; Antiviral Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Erythromycin; Humans; Male; Metabolic Clearance Rate; Oxidoreductases, N-Demethylating; Pyrazines; Quinolines | 1998 |
Effect of vesnarinone on cardiac function in patients with severe congestive heart failure.
Topics: Aged; Cardiotonic Agents; Echocardiography; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Pyrazines; Quinolines; Ventricular Function, Left | 1998 |
A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators.
Topics: Aged; Agranulocytosis; Angiotensin-Converting Enzyme Inhibitors; Arrhythmias, Cardiac; Cardiotonic Agents; Death, Sudden; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Heart Failure; Humans; Male; Middle Aged; Pyrazines; Quality of Life; Quinolines; Survival Analysis | 1998 |
Effect of inotrope withdrawal on morbidity and mortality in patients with chronic heart failure: results of the vesnarinone trial withdrawal substudy. Vest Withdrawal Substudy Group.
Topics: Cardiotonic Agents; Cause of Death; Chronic Disease; Disease Progression; Follow-Up Studies; Heart Failure; Humans; Middle Aged; Myocardial Contraction; Pyrazines; Quinolines; Retrospective Studies; Substance Withdrawal Syndrome; Survival Rate | 1999 |
Phase I and pharmacokinetic study of the differentiating agent vesnarinone in combination with gemcitabine in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Differentiation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Female; Gemcitabine; Humans; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Pyrazines; Quinolines; Thrombocytopenia; Vomiting | 2000 |
Effects of vesnarinone on peripheral circulating levels of cytokines and cytokine receptors in patients with heart failure: a report from the Vesnarinone Trial.
Topics: Cardiotonic Agents; Cytokines; Enzyme-Linked Immunosorbent Assay; Female; Heart Failure; Humans; Interleukin-6; Male; Middle Aged; Pyrazines; Quinolines; Receptors, Cytokine; Receptors, Interleukin-6; Receptors, Tumor Necrosis Factor; Tumor Necrosis Factor-alpha | 2001 |
Visualization and dynamics of multidimensional health-related quality-of-life-adjusted overall survival: a new analytic approach.
Topics: Cardiotonic Agents; Cohort Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Heart Failure; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pyrazines; Quality of Life; Quality-Adjusted Life Years; Quinolines; Sickness Impact Profile; Stochastic Processes; Surveys and Questionnaires; Treatment Outcome; Ventricular Function, Left | 2014 |
149 other study(ies) available for vesnarinone and pyrazines
| Article | Year |
|---|---|
[Solid phase clean-up and determination of vesnarinone in plasma by high performance liquid chromatography].
Topics: Animals; Cardiotonic Agents; Chromatography, High Pressure Liquid; Dogs; Pyrazines; Quinolines | 1992 |
[Obtaining natural light photostability of drugs from lamp light exposure experiments].
Topics: Drug Stability; Light; Pyrazines; Quinolines; Riboflavin; Sulfadiazine; Vitamin K | 1992 |
[Effect of Chinese-made vesnarinone on experimental heart failure of dog].
Topics: Animals; Cardiac Output; Cardiotonic Agents; Dogs; Female; Heart Failure; Hemodynamics; Male; Myocardial Contraction; Pentobarbital; Pyrazines; Quinolines; Stimulation, Chemical | 1992 |
Left ventricular contractility and energetic cost in disease models--an approach from the pressure-volume diagram.
Topics: Animals; Calcium; Disease Models, Animal; Dogs; Epinephrine; Heart Diseases; Myocardial Contraction; Oxygen Consumption; Propranolol; Pyrazines; Quinolines; Rabbits | 1992 |
The inhibitory effects of a positive inotropic quinolinone derivative, 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)- quinolinone (OPC-8212), on bone-marrow progenitor cells and peripheral lymphocytes.
Topics: Bone Marrow; Bone Marrow Cells; Cardiotonic Agents; Cells, Cultured; Fibroblasts; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Interferon-gamma; Lymphocyte Activation; Lymphocytes; Pyrazines; Quinolines; Skin | 1992 |
[Influences of new synthetic drug vesnarinone on circulatory and respiratory function of dogs].
Topics: Animals; Blood Flow Velocity; Blood Pressure; Cardiotonic Agents; Carotid Arteries; Dogs; Female; Heart Rate; Male; Pyrazines; Quinolines; Respiration; Stimulation, Chemical | 1991 |
[Studies on the mutagenicity of vesnarinone].
Topics: Animals; Bone Marrow Cells; Chromosome Aberrations; Female; Male; Mice; Micronucleus Tests; Mutagenicity Tests; Pyrazines; Quinolines | 1991 |
[Determination of trace chloride and sulfate in drugs by ion chromatography].
Topics: Charcoal; Chlorides; Chromatography, Ion Exchange; Magnesium; Magnesium Silicates; Pyrazines; Quinolines; Silicic Acid; Sulfates | 1991 |
Effect of the cardiac inotropic drug, OPC 8212, on pituitary-thyroid function in the rat.
Topics: Animals; Bile; Cardiotonic Agents; Cytochrome P-450 Enzyme System; Glucuronosyltransferase; Iodine; Liver; Male; Osmolar Concentration; Pituitary Gland; Pyrazines; Quinolines; Rats; Rats, Inbred F344; Thyroid Gland; Thyroid Hormones; Thyrotropin | 1991 |
[How to select newly-developed oral inotropic agents: an evaluation based on their effects on heart rate and arrhythmias].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiomyopathy, Dilated; Cardiotonic Agents; Circadian Rhythm; Digitalis; Drug Evaluation; Electrocardiography, Ambulatory; Ethanolamines; Female; Heart Rate; Humans; Male; Middle Aged; Plants, Medicinal; Plants, Toxic; Propanolamines; Pyrazines; Quinolines; Xamoterol | 1990 |
[Effect of a new positive inotropic agent (OPC-8212) on intracellular potential of isolated canine ventricular papillary muscle].
Topics: Action Potentials; Animals; Cardiotonic Agents; Dogs; Female; In Vitro Techniques; Male; Membrane Potentials; Microelectrodes; Myocardial Contraction; Papillary Muscles; Pyrazines; Quinolines; Stimulation, Chemical | 1990 |
Evidence for possible increase of sodium channel open time and involvement of Na/Ca exchange by a new positive inotropic drug: OPC-8212.
Topics: Animals; Biological Transport; Calcium; Cardiotonic Agents; Electrophysiology; Guinea Pigs; In Vitro Techniques; Ion Channels; Lidocaine; Myocardium; Purkinje Fibers; Pyrazines; Quinolines; Sodium; Veratrine | 1985 |
Effects of new inotropic agents on cyclic nucleotide metabolism and calcium transients in canine ventricular muscle.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; Aequorin; Aminopyridines; Amrinone; Animals; Calcium; Carbachol; Cardiotonic Agents; Colforsin; Cyclic AMP; Dogs; Dose-Response Relationship, Drug; Enoximone; Female; Imidazoles; Male; Milrinone; Myocardial Contraction; Myocardium; Nifedipine; Nucleotides, Cyclic; Pyrazines; Pyridones; Quinolines; Time Factors | 1986 |
Membrane current changes responsible for the positive inotropic effect of OPC-8212, a new positive inotropic agent, in single ventricular cells of the guinea pig heart.
Topics: 1-Methyl-3-isobutylxanthine; Action Potentials; Animals; Calcium; Electric Conductivity; Guinea Pigs; Heart; Myocardial Contraction; Myocardium; Potassium; Pyrazines; Quinolines | 1987 |
Antitachycardiac effect of OPC-8212, a novel cardiotonic agent, on tachycardiac responses of guinea pig isolated right atria to isoproterenol and histamine.
Topics: Animals; Cardiotonic Agents; Dose-Response Relationship, Drug; Female; Guinea Pigs; Heart Atria; Heart Rate; Histamine; Isoproterenol; Male; Nadolol; Pyrazines; Quinolines; Solvents; Tachycardia; Thiophenes | 1987 |
New positive inotropic agent OPC-8212 modulates single Ca2+ channels in ventricular myocytes of guinea pig.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; Animals; Caffeine; Calcium Channels; Cardiotonic Agents; Colforsin; Cyclic AMP; Depression, Chemical; Dose-Response Relationship, Drug; Guinea Pigs; Heart Ventricles; Isoproterenol; Myocardium; Phosphorylation; Pyrazines; Quinolines | 1989 |
Rate-dependent electrophysiological effects of OPC-8212: comparison to sotalol.
Topics: Action Potentials; Animals; Cardiotonic Agents; Dogs; Electrophysiology; Female; Heart Rate; Male; Membrane Potentials; Pyrazines; Quinolines; Sotalol | 1989 |
Cyclic AMP-dependent and cyclic AMP-independent actions of a novel cardiotonic agent, OPC-8212.
Topics: Action Potentials; Animals; Cardiotonic Agents; Cattle; Cyclic AMP; Cyclic GMP; Electrophysiology; In Vitro Techniques; Membrane Potentials; Phosphodiesterase Inhibitors; Purkinje Fibers; Pyrazines; Quinolines; Sodium; Solvents; Time Factors | 1988 |
[Effects of a new positive inotropic agent, OPC-8212 in patients with effort angina--comparison with beta-blocker, metoprolol].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angina Pectoris; Cardiotonic Agents; Electrocardiography; Exercise Test; Female; Heart Rate; Humans; Male; Metoprolol; Middle Aged; Pyrazines; Quinolines | 1988 |
OPC-8212 in the treatment of congestive heart failure: results of a pilot study.
Topics: Aged; Cardiotonic Agents; Exercise Test; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Pilot Projects; Pyrazines; Quinolines | 1988 |
Pharmacokinetic profile of OPC-8212 in humans: a new, nonglycosidic, inotropic agent.
Topics: Adult; Cardiotonic Agents; Humans; Male; Pyrazines; Quinolines | 1988 |
Metabolism of a new positive inotropic agent, 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)- quinolinone (OPC-8212) in the rat, mouse, dog, monkey and human.
Topics: Adult; Animals; Cardiotonic Agents; Chemical Phenomena; Chemistry; Humans; Macaca fascicularis; Magnetic Resonance Spectroscopy; Male; Mass Spectrometry; Mice; Microsomes, Liver; Pyrazines; Quinolines; Rats; Rats, Inbred Strains | 1988 |
[Usefulness of OPC-8212, an inotropic agent, in patients with chronic congestive heart failure--a multiple dose evaluation on its effect and arrhythmogenesis].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Cardiotonic Agents; Drug Evaluation; Female; Heart Failure; Humans; Male; Middle Aged; Pyrazines; Quinolines | 1988 |
A new cardiotonic agent, OPC-8212, elevates the myocardial oxygen consumption versus pressure-volume area (PVA) relation in a similar manner to catecholamines and calcium in canine hearts.
Topics: Animals; Calcium; Cardiotonic Agents; Catecholamines; Dogs; Energy Metabolism; Myocardial Contraction; Myocardium; Oxygen Consumption; Pyrazines; Quinolines | 1988 |
Effect of OPC-8212 (2(1H)-quinolinone), a new inotropic agent, on myocardial energy metabolism in patients with coronary heart disease.
Topics: Adult; Aged; Cardiotonic Agents; Coronary Circulation; Coronary Disease; Energy Metabolism; Heart; Hemodynamics; Humans; Male; Middle Aged; Myocardium; Oxygen Consumption; Pyrazines; Quinolines | 1988 |
Acute hemodynamic effects of a new inotropic agent (OPC-8212) in patients with congestive heart failure.
Topics: Adult; Aged; Cardiac Output; Cardiotonic Agents; Drug Evaluation; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Pyrazines; Quinolines; Stroke Volume | 1987 |
Cardiotonic activity of a new inotropic agent, 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)- quinolinone (OPC-8212), in the dog with and without beta-blocker and Ca++-antagonist pretreatment.
Topics: Animals; Benzazepines; Blood Pressure; Cardiac Output; Cardiotonic Agents; Diltiazem; Dogs; Dose-Response Relationship, Drug; Heart Rate; Hemodynamics; Isoproterenol; Pharmaceutical Vehicles; Pyrazines; Quinolines; Thiophenes | 1986 |
Acute hemodynamic effects of a new inotropic agent, OPC-8212, on severe congestive heart failure.
Topics: Administration, Oral; Adult; Aged; Cardiac Output; Cardiomyopathy, Dilated; Cardiotonic Agents; Coronary Disease; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Myocardial Contraction; Myocarditis; Pyrazines; Quinolines | 1986 |
Effects of OPC-8212, a new positive inotropic agent, on canine ventricular arrhythmias.
Topics: Animals; Arrhythmias, Cardiac; Digitalis Glycosides; Dogs; Epinephrine; Female; Heart Ventricles; Male; Myocardial Contraction; Pyrazines; Quinolines; Stimulation, Chemical; Time Factors | 1986 |
Beneficial effect of OPC-8212 (3,4-dihydro-6-(4-(3,4-dimethoxy benzoyl)-1-piperazinyl)-2(1H)-quinolinone on myocardial oxygen consumption in dogs with ischemic heart failure.
Topics: Animals; Coronary Disease; Dogs; Drug Evaluation, Preclinical; Hemodynamics; Oxygen Consumption; Pyrazines; Quinolines | 1986 |
Oral OPC-8212 for the treatment of congestive heart failure: hemodynamic improvement and increased exercise capacity.
Topics: Administration, Oral; Aged; Blood Pressure; Cardiotonic Agents; Female; Heart Failure; Heart Rate; Hemodynamics; Humans; Male; Middle Aged; Physical Exertion; Pyrazines; Quinolines; Radionuclide Imaging; Stroke Volume | 1986 |
High-performance liquid chromatographic procedure for the determination of a new positive inotropic agent, 3,4-dihydro-6-[4-(3,4-(dimethoxybenzoyl)-1-piperazinyl]-2(1H)- quinolinone, in human plasma and urine.
Topics: Cardiotonic Agents; Chromatography, High Pressure Liquid; Half-Life; Humans; Kinetics; Male; Pyrazines; Quinolines | 1985 |
Involvement of cyclic AMP in the positive inotropic effect of OPC-8212, a new cardiotonic agent, on the canine ventricular muscle.
Topics: Animals; Atenolol; Carbachol; Cardiotonic Agents; Cyclic AMP; Dogs; Female; Heart; In Vitro Techniques; Isoproterenol; Male; Myocardial Contraction; Myocardium; Pyrazines; Quinolines; Stimulation, Chemical; Thiophenes | 1984 |
In vitro and in vivo studies of 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)- quinolinone (OPC-8212), a novel positive inotropic drug, in various animals.
Topics: Aminopyridines; Amrinone; Animals; Blood Pressure; Cardiotonic Agents; Cardiovascular System; Cats; Dobutamine; Dogs; Female; Guinea Pigs; Heart Rate; In Vitro Techniques; Male; Myocardial Contraction; Phentolamine; Pindolol; Pyrazines; Quinolines; Rabbits; Rats; Sodium-Potassium-Exchanging ATPase; Theophylline | 1984 |
Mode and mechanism of action of 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)- quinolinone (OPC-8212), a novel positive inotropic drug, on the dog heart.
Topics: Animals; Atrioventricular Node; Cardiotonic Agents; Coronary Circulation; Cyclic AMP; Dogs; Female; Heart; In Vitro Techniques; Male; Membrane Potentials; Myocardial Contraction; Papillary Muscles; Phosphodiesterase Inhibitors; Pyrazines; Quinolines; Sinoatrial Node | 1984 |
Positive inotropic effect of 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1 -piperazinyl]-2(1H)-quinolinone (OPC-8212) and mechanism of action in guinea pig ventricular myocardium.
Topics: Animals; Carbachol; Cardiotonic Agents; Cimetidine; Cyclic AMP; Dose-Response Relationship, Drug; Female; Guinea Pigs; Histamine; In Vitro Techniques; Isoproterenol; Male; Membrane Potentials; Myocardial Contraction; Propranolol; Pyrazines; Quinolines; Reserpine | 1984 |
Studies on positive inotropic agents. I. Synthesis of 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)- quinolinone and related compounds.
Topics: Animals; Cardiotonic Agents; Chemical Phenomena; Chemistry; Dogs; Heart Rate; In Vitro Techniques; Myocardial Contraction; Pyrazines; Quinolines | 1984 |
Physico-chemical properties and stabilities of a new positive inotropic agent, 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl] -2(1H)-quinolinone (OPC-8212).
Topics: Cardiotonic Agents; Chemical Phenomena; Chemistry; Chromatography, High Pressure Liquid; Drug Stability; Hydrogen-Ion Concentration; Pyrazines; Quinolines; Solubility | 1984 |
Effects of 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl] -2(1H)-quinolinone (OPC-8212), a new inotropic agent, on cardiotonic activity and coronary hemodynamics.
Topics: Animals; Cardiotonic Agents; Coronary Circulation; Dogs; Dose-Response Relationship, Drug; Heart Rate; In Vitro Techniques; Isoproterenol; Myocardial Contraction; Myocardium; Oxygen Consumption; Pyrazines; Quinolines | 1984 |
Effects of a new positive inotropic agent, 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)- quinolinone (OPC-8212) and its solvent sulfolane on isolated heart preparations of the rat, guinea pig, and dog.
Topics: Animals; Calcium Channel Blockers; Cardiotonic Agents; Coronary Circulation; Dogs; Female; Guinea Pigs; In Vitro Techniques; Male; Myocardial Contraction; Ouabain; Pyrazines; Quinolines; Rats; Solvents; Thiophenes | 1984 |
Electro-mechanical effects of 3, 4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-qu inolinone (OPC-8212), a new positive inotropic agent. Isolated adult canine Purkinje strands and ventricular trabeculae.
Topics: Action Potentials; Animals; Cardiotonic Agents; Cats; Dogs; Dose-Response Relationship, Drug; Female; Heart; Heart Conduction System; In Vitro Techniques; Male; Myocardial Contraction; Purkinje Fibers; Pyrazines; Quinolines | 1984 |
Effect of 3, 4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-qu inolinone (OPC-8212) on the membrane currents of rabbit sino-atrial node cells.
Topics: Action Potentials; Animals; Cardiotonic Agents; Dose-Response Relationship, Drug; Female; In Vitro Techniques; Male; Pyrazines; Quinolines; Rabbits; Sinoatrial Node | 1984 |
The effect of a new positive inotropic agent, 3, 4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-qu inolinone (OPC-8212), on thin bundles of skinned fibers from cardiac muscle.
Topics: Animals; Anura; Calcium; Cardiotonic Agents; Guinea Pigs; Heart; In Vitro Techniques; Myocardial Contraction; Pyrazines; Quinolines; Sarcoplasmic Reticulum; Xenopus laevis | 1984 |
Studies on the mechanism of action of 3, 4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-qu inolinone (OPC-8212), a new positive inotropic drug. Enzyme activities and Ca2+ transport processes of sarcolemma and intracellular organelles.
Topics: Animals; Biological Transport; Calcium; Cardiotonic Agents; Heart; In Vitro Techniques; Mitochondria, Heart; Myocardium; Oxygen Consumption; Potassium; Pyrazines; Quinolines; Rabbits; Rats; Sarcolemma; Sarcoplasmic Reticulum | 1984 |
Positive inotropic effect of 3, 4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-qu inolinone (OPC-8212) in the dog with experimentally-induced right-sided heart failure.
Topics: Administration, Oral; Aminopyridines; Amrinone; Animals; Blood Pressure; Cardiotonic Agents; Dobutamine; Dogs; Dose-Response Relationship, Drug; Heart Failure; Heart Rate; Injections, Intravenous; Male; Myocardial Contraction; Pyrazines; Quinolines | 1984 |
Pharmacokinetics of a new positive inotropic agent, 3, 4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-qu inolinone (OPC-8212), in the rat, rabbit, beagle dog and rhesus monkey.
Topics: Animals; Autoradiography; Bile; Carbon Radioisotopes; Cardiotonic Agents; Dogs; Feces; Female; Kinetics; Liver; Macaca mulatta; Male; Pregnancy; Protein Binding; Pyrazines; Quinolines; Rabbits; Rats; Species Specificity | 1984 |
Neutropenia occurring during treatment with vesnarinone (OPC-8212).
Topics: Cardiomyopathy, Dilated; Cardiotonic Agents; Clinical Trials as Topic; Europe; Female; Granulocyte Colony-Stimulating Factor; Humans; Incidence; Male; Middle Aged; Neutropenia; Pyrazines; Quinolines; Risk Factors; Time Factors; United States | 1994 |
Alterations of the cytoskeletal organization in tumor cell lines by a cardiotonic drug, vesnarinone, through protein tyrosine phosphorylation.
Topics: 3T3 Cells; Adenosine Triphosphate; Animals; Carcinoma, Squamous Cell; Cardiotonic Agents; Catechols; Cell Communication; Cell Line; Cell Line, Transformed; Cytoskeleton; Electrophoresis, Polyacrylamide Gel; ErbB Receptors; Genes, src; Humans; Immunoblotting; Lung Neoplasms; Mice; Nitriles; Phosphoproteins; Phosphotyrosine; Protein-Tyrosine Kinases; Pyrazines; Quinolines; Tubulin; Tumor Cells, Cultured; Tyrosine; Tyrphostins; Vimentin | 1995 |
Sequential monitoring of survival data with the Wilcoxon statistic.
Topics: Biometry; Cardiotonic Agents; Clinical Trials as Topic; Follow-Up Studies; Heart Failure; Humans; Life Tables; Models, Statistical; Pyrazines; Quinolines; Randomized Controlled Trials as Topic; Research Design; Survival Analysis; Time Factors | 1995 |
Vesnarinone inhibits induction of nitric oxide synthase in J774 macrophages and rat cardiac myocytes in culture.
Topics: Animals; Calmodulin-Binding Proteins; Cell Line; Cells, Cultured; Interferon-gamma; Lipopolysaccharides; Macrophages; Mice; Myocardium; NADPH Dehydrogenase; Nitric Oxide Synthase; Nitrites; Polymerase Chain Reaction; Pyrazines; Quinolines; Rats; Rats, Wistar; RNA, Messenger | 1995 |
Vesnarinone inhibits nucleoside and nucleobase transport.
Topics: Adenine; Animals; Biological Transport; Cell Line; CHO Cells; Cricetinae; Humans; Nucleosides; Pyrazines; Quinolines; Thymidine; Uracil; Uridine | 1995 |
Kinetic study on the photostability of solid vesnarinone and the equivalent relationship between daylight and lamplight.
Topics: Cardiotonic Agents; Drug Stability; Kinetics; Light; Mathematics; Photochemistry; Pyrazines; Quinolines | 1995 |
Relaxing effect of vesnarinone (OPC-8212) on the tracheal muscle strips isolated from guinea pigs.
Topics: 1-Methyl-3-isobutylxanthine; Airway Resistance; Animals; Carbachol; Drug Interactions; Female; Guinea Pigs; Histamine; In Vitro Techniques; Isoproterenol; Male; Potassium; Propranolol; Pyrazines; Quinolines; Reserpine; Trachea | 1993 |
Characteristics of antitumor activity of 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]- 2(1H)-quinolinone (vesnarinone) against a human adenoid squamous carcinoma-forming cell line grown in athymic nude mice.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Differentiation; DNA Damage; Drug Evaluation, Preclinical; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Pyrazines; Quinolines; Transplantation, Heterologous; Tumor Cells, Cultured | 1995 |
[Inotropic effect of novel domestic cardiotonic agent, vesnarinone--test in vitro].
Topics: Amrinone; Animals; Cardiotonic Agents; Dose-Response Relationship, Drug; Female; Guinea Pigs; In Vitro Techniques; Male; Milrinone; Myocardial Contraction; Pyrazines; Pyridones; Quinolines; Rabbits; Stimulation, Chemical | 1994 |
Metabolism of vesnarinone by activated neutrophils: implications for vesnarinone-induced agranulocytosis.
Topics: Agranulocytosis; Albumins; Cardiotonic Agents; Chromatography, High Pressure Liquid; Glutathione; Humans; Hydrogen Peroxide; Hypochlorous Acid; In Vitro Techniques; Influenza Vaccines; Magnetic Resonance Spectroscopy; Mass Spectrometry; Neutrophil Activation; Neutrophils; Oxidation-Reduction; Peroxidase; Protein Binding; Pyrazines; Quinolines | 1994 |
Vesnarinone prolongs survival and reduces lethality in a murine model of lethal endotoxemia.
Topics: Animals; Disease Models, Animal; Female; Lipopolysaccharides; Mice; Mice, Inbred BALB C; Pyrazines; Quinolines; Toxemia; Tumor Necrosis Factor-alpha | 1994 |
Treatment of virus-induced myocardial injury with a novel immunomodulating agent, vesnarinone. Suppression of natural killer cell activity and tumor necrosis factor-alpha production.
Topics: Amrinone; Animals; Cardiomyopathies; Cardiovirus Infections; Encephalomyocarditis virus; Female; Immunosuppressive Agents; Killer Cells, Natural; Male; Mice; Mice, Inbred DBA; Mice, Inbred Strains; Myocardium; Pregnancy; Pyrazines; Quinolines; Time Factors; Tumor Necrosis Factor-alpha | 1994 |
Vesnarinone, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure.
Topics: Blood; Cardiotonic Agents; Cytokines; Enzyme-Linked Immunosorbent Assay; Female; Heart Failure; Humans; In Vitro Techniques; Male; Middle Aged; Pyrazines; Quinolines | 1994 |
Effects of vesnarinone (OPC-8212) on Ca(2+)-activated K channels and cytosolic Ca2+ in cultured smooth muscle cells from porcine coronary artery.
Topics: Amrinone; Animals; Arteries; Calcium; Carbachol; Cardiotonic Agents; Cells, Cultured; Coronary Vessels; Cyclic AMP; Cytosol; Muscle, Smooth, Vascular; Potassium Channels; Pyrazines; Quinolines; Swine | 1994 |
Vesnarinone induced agranulocytosis.
Topics: Aged; Agranulocytosis; Bone Marrow; Colony-Forming Units Assay; Female; Humans; Pyrazines; Quinolines | 1993 |
Vesnarinone inhibits production of HIV-1 in cultured cells.
Topics: Antiviral Agents; Cell Fusion; Cell Separation; Cells, Cultured; Cytokines; Dose-Response Relationship, Drug; HIV Protease; HIV-1; Humans; Leukocytes, Mononuclear; Macrophages; Pyrazines; Quinolines; T-Lymphocytes; Virus Replication | 1993 |
Ionic basis for OPC-8212-induced increase in action potential duration in isolated rabbit, guinea pig and human ventricular myocytes.
Topics: Action Potentials; Animals; Cardiotonic Agents; Electrophysiology; Female; Guinea Pigs; Heart; Heart Ventricles; Humans; In Vitro Techniques; Male; Membrane Potentials; Myocardial Contraction; Potassium; Pyrazines; Quinolines; Rabbits; Sodium; Veratrine | 1993 |
[Synchronous investigation of the effects of vesnarinone on action potential and muscle tension of isolated rabbit's ventricular papillary muscle].
Topics: Action Potentials; Animals; Cardiotonic Agents; Female; In Vitro Techniques; Male; Microelectrodes; Myocardial Contraction; Papillary Muscles; Pyrazines; Quinolines; Rabbits; Stimulation, Chemical | 1993 |
Inhibition of cytokine production by a new inotropic agent, vesnarinone, in human lymphocytes, T cell line, and monocytic cell line.
Topics: Adult; Cardiotonic Agents; Cytokines; Humans; Interferon-gamma; Interleukin-1; Interleukin-2; Lymphocytes; Monocytes; Pyrazines; Quinolines; T-Lymphocytes; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 1994 |
Vesnarinone for heart failure.
Topics: Cardiotonic Agents; Heart Failure; Humans; Pyrazines; Quinolines | 1994 |
Vesnarinone for heart failure.
Topics: Cardiotonic Agents; Heart Failure; Humans; Pyrazines; Quinolines | 1994 |
Vesnarinone for heart failure.
Topics: Cardiotonic Agents; Heart Failure; Hemodynamics; Humans; Myocardial Contraction; Pyrazines; Quinolines; Stimulation, Chemical | 1994 |
Two isoforms of cGMP-inhibited cyclic nucleotide phosphodiesterases in human tissues distinguished by their responses to vesnarinone, a new cardiotonic agent.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aorta; Blood Platelets; Calcium; Calmodulin; Cardiotonic Agents; Cilostazol; Cyclic AMP; Cyclic GMP; Enoximone; Humans; Isoenzymes; Kidney; Myocardium; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Pyrazines; Quinolines; Tetrazoles | 1993 |
Ca2+(-)dependent and Ca2+(-)independent vasorelaxation induced by cardiotonic phosphodiesterase inhibitors.
Topics: Animals; Bucladesine; Calcium; Cardiotonic Agents; Colforsin; In Vitro Techniques; Male; Phosphodiesterase Inhibitors; Pyrazines; Quinolines; Rats; Rats, Wistar; Vasodilation; Verapamil | 1993 |
The search for the ideal positive inotropic agent.
Topics: Cardiotonic Agents; Heart Failure; Humans; Myocardial Contraction; Pyrazines; Quinolines | 1993 |
Cell differentiation induced by poly(ADP-ribose) synthetase inhibitors.
Topics: Animals; Carbolines; Cell Differentiation; Enzyme Inhibitors; Heterocyclic Compounds; Kinetics; Mice; Poly(ADP-ribose) Polymerase Inhibitors; Pyrazines; Quinolines; Structure-Activity Relationship; Teratocarcinoma; Tumor Cells, Cultured | 1995 |
Induction of differentiation and enhancement of vincristine sensitivity of human erythroleukemia HEL cells by vesnarinone, a positive inotropic agent.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Calcium; Cardiotonic Agents; Cell Differentiation; Drug Interactions; Drug Resistance; Humans; Leukemia, Erythroblastic, Acute; Leukemia, Myeloid; Muramidase; Pyrazines; Quinolines; Stimulation, Chemical; Tretinoin; Tumor Cells, Cultured; Vincristine | 1996 |
Inotropic agent vesnarinone inhibits cytokine production and E-selectin expression in human umbilical vein endothelial cells.
Topics: 8-Bromo Cyclic Adenosine Monophosphate; Amrinone; Cardiotonic Agents; Cell Adhesion; Cells, Cultured; Colforsin; Cyclic AMP; Cytokines; Depression, Chemical; E-Selectin; Endothelium, Vascular; Gene Expression Regulation; Heart Failure; Hematopoietic Cell Growth Factors; Humans; Intercellular Adhesion Molecule-1; Interleukin-1; Monocytes; Neutropenia; Pyrazines; Quinolines; Tumor Necrosis Factor-alpha; Umbilical Veins; Vascular Cell Adhesion Molecule-1 | 1995 |
Nonparametric test of stochastic ordering for multiple longitudinal measures.
Topics: Cardiotonic Agents; Double-Blind Method; Heart Failure; Humans; Longitudinal Studies; Multicenter Studies as Topic; Multivariate Analysis; Pyrazines; Quinolines; Randomized Controlled Trials as Topic; Research Design; Statistics, Nonparametric; Stochastic Processes | 1995 |
Inhibition of CD4 cross-linking-induced lymphocytes apoptosis by vesnarinone as a novel immunomodulating agent: vesnarinone inhibits Fas expression and apoptosis by blocking cytokine secretion.
Topics: Adjuvants, Immunologic; Antibodies, Monoclonal; Apoptosis; CD4 Antigens; CD4-Positive T-Lymphocytes; Depression, Chemical; fas Receptor; Gene Expression Regulation; HIV Seronegativity; Humans; Immunologic Capping; Lymphokines; Pyrazines; Quinolines | 1996 |
Role of cytokines in the syndrome of heart failure.
Topics: Adrenergic beta-Agonists; Amrinone; Animals; Cardiotonic Agents; Cytokines; Heart Failure; Humans; Killer Cells, Natural; Myocarditis; Phosphodiesterase Inhibitors; Pyrazines; Quinolines; Tumor Necrosis Factor-alpha | 1996 |
Positive inotropic agents: a double-edged sword for chronic heart failure.
Topics: Cardiotonic Agents; Chronic Disease; Clinical Trials as Topic; Dose-Response Relationship, Drug; Heart Failure; Humans; Pyrazines; Pyridazines; Quinolines | 1996 |
[Suppression of granulopoiesis by vesnarinone].
Topics: Adult; Agranulocytosis; Apoptosis; Cardiotonic Agents; Cells, Cultured; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cells; Humans; Male; Middle Aged; Pyrazines; Quinolines | 1996 |
[Effects of vesnarinone on L-type single Ca2+ channel current in cultured ventricular myocytes of embryonic chick].
Topics: Animals; Calcium Channels; Cardiotonic Agents; Cells, Cultured; Chick Embryo; Milrinone; Myocardium; Patch-Clamp Techniques; Phosphodiesterase Inhibitors; Pyrazines; Pyridones; Quinolines | 1995 |
Inotropic agents differentially inhibit the induction of nitric oxide synthase by endotoxin in cultured macrophages.
Topics: 8-Bromo Cyclic Adenosine Monophosphate; Amrinone; Animals; Cardiotonic Agents; Cell Line; Culture Media; Lipopolysaccharides; Macrophages; Mice; Nitric Oxide Synthase; Nitrites; Phosphodiesterase Inhibitors; Pyrazines; Pyridazines; Quinolines | 1996 |
Effects of vesnarinone, a novel orally active inotropic agent with an immunosuppressive action, on experimental cardiac transplantation in rats.
Topics: Acute Disease; Animals; Cardiotonic Agents; Chronic Disease; Graft Rejection; Heart Transplantation; Immunosuppressive Agents; Male; Pyrazines; Quinolines; Rats; Rats, Inbred BN; Rats, Inbred F344; Rats, Inbred Lew | 1996 |
Differential modulation of cytokine production by drugs: implications for therapy in heart failure.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; 3',5'-Cyclic-GMP Phosphodiesterases; 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; 8-Bromo Cyclic Adenosine Monophosphate; Amrinone; Cells, Cultured; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 3; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclic Nucleotide Phosphodiesterases, Type 5; Heart Failure; Humans; Interleukin-1; Interleukin-6; Kinetics; Leukocytes, Mononuclear; Lipopolysaccharides; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Piperidines; Pyrazines; Pyridazines; Quinazolines; Quinolines; Tumor Necrosis Factor-alpha | 1996 |
Prolongation of murine cardiac allograft survival with vesnarinone.
Topics: Adjuvants, Immunologic; Analysis of Variance; Animals; Cells, Cultured; Graft Survival; Heart Transplantation; Interferon-gamma; Interleukin-2; Male; Mice; Mice, Inbred Strains; Pyrazines; Quinolines; Spleen; T-Lymphocytes, Cytotoxic; Time Factors; Transplantation, Heterotopic; Transplantation, Homologous | 1997 |
Induction of cyclin-dependent kinase inhibitor, p21WAF1, by treatment with 3,4-dihydro-6-[4-(3,4)-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-quinoline (vesnarinone) in a human salivary cancer cell line with mutant p53 gene.
Topics: Antineoplastic Agents; Carcinoma, Adenosquamous; Cell Differentiation; Cell Division; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Gene Expression Regulation, Neoplastic; Genes, p53; Humans; Mutation; Polymerase Chain Reaction; Polymorphism, Single-Stranded Conformational; Pyrazines; Quinolines; Salivary Gland Neoplasms; Transforming Growth Factor beta; Tumor Cells, Cultured | 1997 |
Effect of vesnarinone, a quinolinone derivative, on the growth of leukemic blasts in acute myelogenous leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Cell Division; Colony-Forming Units Assay; Female; Hematopoiesis; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Pyrazines; Quinolines; Tumor Cells, Cultured | 1997 |
Through the looking glass: a positive inotropic drug and ischemic preconditioning.
Topics: 5'-Nucleotidase; Adenosine; Animals; Cardiotonic Agents; Dogs; Drug Approval; Enzyme Activation; Heart Failure; Humans; Ischemic Preconditioning, Myocardial; Myocardial Infarction; Myocardium; Neutropenia; Protein Kinase C; Pyrazines; Quinolines; Second Messenger Systems | 1997 |
Vesnarinone limits infarct size via adenosine-dependent mechanisms in the canine heart.
Topics: 5'-Nucleotidase; Adenosine; Adenosine Diphosphate; Animals; Cardiotonic Agents; Dipyridamole; Dogs; Enzyme Activation; Enzyme Inhibitors; Infusions, Intra-Arterial; Ion Channel Gating; Myocardial Infarction; Myocardial Reperfusion Injury; Potassium Channels; Pyrazines; Quinolines; Receptors, Purinergic P1; Theophylline | 1997 |
Effects of vesnarinone on the bone marrow stromal cell-dependent proliferation and differentiation of HL60 cells in vitro.
Topics: Bone Marrow; Bone Marrow Cells; Cardiotonic Agents; Cell Differentiation; Cell Division; Cells, Cultured; Gene Expression; HL-60 Cells; Humans; Macrophage-1 Antigen; Muramidase; Oxidation-Reduction; Peroxidase; Pyrazines; Quinolines | 1997 |
Vesnarinone inhibits immune-mediated but not Fas (CD95) agonist-mediated hepatic injury.
Topics: Acute-Phase Reaction; Animals; Antibodies, Monoclonal; Autoimmune Diseases; Chemical and Drug Induced Liver Injury; Concanavalin A; fas Receptor; Liver Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Pyrazines; Quinolines; Rats; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 1997 |
A quinolinone derivative, vesnarinone (OPC-8212), significantly inhibits the in vitro and in vivo growth of human pancreatic cancer cell lines.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Division; Cell Survival; Collagen; Drug Combinations; Extracellular Matrix; Humans; Laminin; Mice; Mice, Nude; Neoplasm Invasiveness; Pancreatic Neoplasms; Proteoglycans; Pyrazines; Quinolines; Transplantation, Heterologous; Tumor Cells, Cultured | 1997 |
Vesnarinone exhibits antitumor effect against myeloid leukemia cells via apoptosis.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Cell Division; DNA Fragmentation; Dose-Response Relationship, Drug; fas Receptor; Female; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Quinolines; Tumor Cells, Cultured | 1997 |
Possible involvement of bone marrow stromal cells in agranulocytosis caused by vesnarinone treatment.
Topics: Agranulocytosis; Antineoplastic Agents; Bone Marrow Cells; Cell Differentiation; Cell Division; Cell Line; Colony-Forming Units Assay; Cytokines; Humans; Pyrazines; Quinolines; Stromal Cells | 1997 |
[Inotropic effect of novel cardiotonic agent, vesnarinone--tests on anaesthetized dogs].
Topics: Animals; Cardiotonic Agents; Dogs; Female; Male; Myocardial Contraction; Pyrazines; Quinolines; Stimulation, Chemical; Stroke Volume | 1996 |
Vesnarinone prolongs action potential duration without reverse frequency dependence in rabbit ventricular muscle by blocking the delayed rectifier K+ current.
Topics: Action Potentials; Adjuvants, Immunologic; Animals; Anti-Arrhythmia Agents; Delayed Rectifier Potassium Channels; Electric Conductivity; Male; Myocardium; Papillary Muscles; Piperidines; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Pyrazines; Pyridines; Quinolines; Rabbits; Reaction Time; Ventricular Function | 1997 |
[Drug therapy of congestive heart failure].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Cardiotonic Agents; Digitalis; Diuretics; Heart Failure; Humans; Phosphodiesterase Inhibitors; Plants, Medicinal; Plants, Toxic; Pyrazines; Quinolines; Vasodilator Agents | 1997 |
Vesnarinone: a new inotropic agent for treating congestive heart failure.
Topics: Cardiotonic Agents; Clinical Trials as Topic; Cytokines; Heart Failure; Hemodynamics; Humans; Pyrazines; Quinolines; Vascular Resistance | 1995 |
Vesnarinone inhibits adenosine uptake in endothelial cells, smooth muscle cells and myocytes, and mediates cytoprotection.
Topics: Adenosine; Animals; Cardiotonic Agents; Cattle; Cell Survival; Cells, Cultured; Endothelium, Vascular; Heart; Humans; Muscle, Smooth, Vascular; Myocardium; Pyrazines; Quinolines | 1997 |
Down-regulation of TSC-22 (transforming growth factor beta-stimulated clone 22) markedly enhances the growth of a human salivary gland cancer cell line in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Cell Transformation, Neoplastic; Clone Cells; DNA, Antisense; DNA, Complementary; Gene Expression Regulation, Neoplastic; Humans; Leucine Zippers; Mice; Mice, Nude; Neoplasm Proteins; Neoplasm Transplantation; Promoter Regions, Genetic; Pyrazines; Quinolines; Recombinant Fusion Proteins; Repressor Proteins; RNA, Messenger; RNA, Neoplasm; Salivary Gland Neoplasms; Transcription Factors; Transcription, Genetic; Transfection; Tumor Cells, Cultured | 1998 |
Induction of TSC-22 by treatment with a new anti-cancer drug, vesnarinone, in a human salivary gland cancer cell.
Topics: Antineoplastic Agents; Cell Cycle; Cell Division; Humans; Neoplasm Proteins; Oligonucleotides, Antisense; Pyrazines; Quinolines; Repressor Proteins; RNA, Messenger; Salivary Gland Neoplasms; Transcription Factors; Tumor Cells, Cultured; Up-Regulation | 1998 |
Effects of isoenzyme selective phosphodiesterase inhibitors on bacterial lipopolysaccharide-induced bronchial hyperreactivity in guinea pigs.
Topics: Acetylcholine; Animals; Bronchial Hyperreactivity; Bronchoalveolar Lavage Fluid; Cilostazol; Guinea Pigs; Isoenzymes; Lipopolysaccharides; Male; Neutrophils; Phosphodiesterase Inhibitors; Pyrazines; Pyrrolidinones; Quinolines; Rolipram; Tetrazoles; Theophylline; Tumor Necrosis Factor-alpha | 1998 |
Effects of vesnarinone on nitric oxide synthesis in rat cardiac myocytes.
Topics: 8-Bromo Cyclic Adenosine Monophosphate; Analysis of Variance; Animals; Animals, Newborn; Bucladesine; Cardiotonic Agents; Cells, Cultured; Culture Media, Conditioned; Cyclic AMP-Dependent Protein Kinase Type II; Cyclic AMP-Dependent Protein Kinases; Dactinomycin; Dose-Response Relationship, Drug; Interleukin-1; Myocardium; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitrites; omega-N-Methylarginine; Protein Synthesis Inhibitors; Pyrazines; Quinolines; Rats; Rats, Sprague-Dawley; Thionucleotides; Tumor Necrosis Factor-alpha | 1998 |
Action-potential duration and contractility in canine cardiac tissues: action of inotropic drugs.
Topics: Action Potentials; Animals; Cardiotonic Agents; Dogs; Female; In Vitro Techniques; Male; Myocardial Contraction; Myocardium; Purkinje Fibers; Pyrazines; Quinolines; Sodium; Sotalol; Tetraethylammonium; Veratrine | 1998 |
Inotropic therapy for heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Cardiotonic Agents; Death, Sudden; Disease Progression; Diuretics; Drug Therapy, Combination; Heart Failure; Humans; Pyrazines; Quinolines | 1998 |
Antitumor effect of vesnarinone on human hepatocellular carcinoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Division; Dose-Response Relationship, Drug; Humans; In Situ Nick-End Labeling; Isoxazoles; Liver Neoplasms; Pyrazines; Quinolines; Tumor Cells, Cultured | 1999 |
Vesnarinone and amrinone reduce the systemic inflammatory response syndrome.
Topics: Adjuvants, Immunologic; Amrinone; Animals; Drug Evaluation, Preclinical; Endotoxemia; Endotoxins; Heart; Inflammation Mediators; Interleukin-1; Lung; Myocardium; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Phosphodiesterase Inhibitors; Pyrazines; Quinolines; Rabbits; Salmonella typhimurium; Systemic Inflammatory Response Syndrome; Time Factors; Tumor Necrosis Factor-alpha | 1999 |
LC/MS/MS analysis of vesnarinone and its principal metabolites in plasma and urine.
Topics: Biotransformation; Cardiotonic Agents; Chromatography, Liquid; Humans; Mass Spectrometry; Pyrazines; Quinolines; Reproducibility of Results; Spectrophotometry, Ultraviolet | 1999 |
Induction of cyclin-dependent kinase inhibitor p21 in vesnarinone-induced differentiation of squamous cell carcinoma cells.
Topics: Apoptosis; Carcinoma, Squamous Cell; Cell Differentiation; Cyclin E; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; G1 Phase; Humans; Mouth Neoplasms; Phosphorylation; Promoter Regions, Genetic; Pyrazines; Quinolines; Retinoblastoma Protein; RNA, Messenger; Transforming Growth Factor beta; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1998 |
Differential response to vesnarinone by cardiac fibroblasts isolated from normal and aortic regurgitant hearts.
Topics: Animals; Aortic Valve Insufficiency; Cardiotonic Agents; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Fibroblasts; Heart; Heart Failure; Pyrazines; Quinolines; Rabbits | 1998 |
Effect of vesnarinone in combination with anti-cancer drugs on lung cancer cell lines.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cell Division; Cisplatin; Coloring Agents; Deoxycytidine; DNA Fragmentation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Flow Cytometry; Gemcitabine; Humans; Lung Neoplasms; Pyrazines; Quinolines; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured | 1999 |
Effects of vesnarinone on cytokine production and activation of murine microglia.
Topics: Animals; Cardiotonic Agents; Cytokines; Genes, MHC Class II; Lipopolysaccharides; Mice; Mice, Inbred C57BL; Microglia; Phosphodiesterase Inhibitors; Pyrazines; Quinolines; Tumor Necrosis Factor-alpha | 1999 |
Severe heart failure: balancing length and quality of life.
Topics: Amrinone; Cardiotonic Agents; Heart Failure; Humans; Milrinone; Phosphodiesterase Inhibitors; Pyrazines; Quality of Life; Quinolines | 1999 |
Chronic heart failure and the quality of life.
Topics: Cardiotonic Agents; Heart Failure; Humans; Milrinone; Palliative Care; Pyrazines; Quality of Life; Quinolines | 1999 |
Chronic heart failure and the quality of life.
Topics: Cardiotonic Agents; Heart Failure; Humans; Pyrazines; Quality of Life; Quinolines | 1999 |
Effects of phosphodiesterase inhibitors on cytokine production by microglia.
Topics: 1-Methyl-3-isobutylxanthine; Amrinone; Animals; Anti-Ulcer Agents; Cilostazol; Colforsin; Dipyridamole; DNA Primers; Gene Expression Regulation, Enzymologic; Interleukin-1; Interleukin-6; Mice; Mice, Inbred C57BL; Microglia; Multiple Sclerosis; Papaverine; Pentoxifylline; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Pyrazines; Pyrrolidinones; Quinolines; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Rolipram; Tetrazoles; Theophylline; Tumor Necrosis Factor-alpha; Vinca Alkaloids; Xanthines | 1999 |
Investigation on SCH00013, a novel cardiotonic agent with Ca++ sensitizing action. 4th communication: influence on experimentally induced ventricular arrhythmia in dogs.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Calcium Channel Agonists; Cardiotonic Agents; Coronary Vessels; Digitalis Glycosides; Dihydropyridines; Dogs; Epinephrine; Female; Heart Ventricles; Hemodynamics; Male; Pyrazines; Pyridazines; Quinolines; Stereoisomerism; Vasoconstrictor Agents; Ventricular Fibrillation | 1999 |
Vesnarinone and glucocorticoids cooperatively induce G1 arrest and have an anti-tumour effect on human non-small cell lung carcinoma cells grown in nude mice.
Topics: Alkaline Phosphatase; Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Division; Dexamethasone; Drug Synergism; G1 Phase; Glucocorticoids; Humans; Lung Neoplasms; Mice; Neoplasm Transplantation; Pyrazines; Quinolines; Retinoblastoma Protein; Tumor Cells, Cultured | 1999 |
Effect of 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)- quinolinone (vesnarinone) on the growth of gastric cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Northern; Carcinoma; Cell Cycle; Cell Cycle Proteins; Cell Division; Cell Nucleus; Humans; Pyrazines; Quinolines; RNA, Messenger; Stomach Neoplasms; Time Factors; Tumor Cells, Cultured | 1999 |
Apoptosis-inducing activity and growth suppression by vesnarinone on human glioma transplanted in nude mice.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Dose-Response Relationship, Drug; Drug Administration Routes; Glioma; Graft Survival; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Pyrazines; Quinolines; Tumor Cells, Cultured | 1999 |
The effect of vesnarinone on TNF alpha production in human peripheral blood mononuclear cells and microglia: a preclinical study for the treatment of multiple sclerosis.
Topics: Adjuvants, Immunologic; Anti-Inflammatory Agents, Non-Steroidal; Antigens, Viral; Cell Division; Cell Line; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Humans; Influenza, Human; Interferon-gamma; Lipopolysaccharides; Microglia; Multiple Sclerosis; Pyrazines; Pyrrolidinones; Quinolines; Rolipram; T-Lymphocytes; Tumor Necrosis Factor-alpha | 1999 |
Inhibitory effects of vesnarinone in the progression of myocardial damage in experimental autoimmune myocarditis in rats.
Topics: Analysis of Variance; Animals; Autoimmune Diseases; Biomarkers; Blotting, Northern; Female; Interleukin-1; Myocarditis; Myocardium; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Pyrazines; Quinolines; Rats; Rats, Inbred Lew; Tumor Necrosis Factor-alpha | 1999 |
Effect of disulfiram-mediated CYP2E1 inhibition on the disposition of vesnarinone.
Topics: Adult; Cardiotonic Agents; Chlorzoxazone; Cytochrome P-450 CYP2E1 Inhibitors; Disulfiram; Drug Interactions; Enzyme Inhibitors; Humans; Male; Pyrazines; Quinolines; Time Factors | 1999 |
Inhibition of hyaluronan synthesis by vesnarinone in cultured human myofibroblasts.
Topics: Cell Line; Enzyme Inhibitors; Glucuronosyltransferase; Glycosyltransferases; Humans; Hyaluronan Synthases; Hyaluronic Acid; Membrane Proteins; Pyrazines; Quinolines; Transferases; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha; Xenopus Proteins | 2000 |
Vesnarinone suppresses TNF-induced activation of NF-kappa B, c-Jun kinase, and apoptosis.
Topics: Apoptosis; Biological Transport; Ceramides; Chloramphenicol O-Acetyltransferase; DNA; DNA-Binding Proteins; Enzyme Activation; Enzyme Inhibitors; Genes, MDR; Genes, Reporter; HeLa Cells; Humans; Hydrogen Peroxide; I-kappa B Proteins; Immunosuppressive Agents; JNK Mitogen-Activated Protein Kinases; Jurkat Cells; Lipid Peroxidation; Lipopolysaccharides; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; NF-kappa B; NF-kappa B p50 Subunit; NF-KappaB Inhibitor alpha; Okadaic Acid; Phosphorylation; Protein Binding; Pyrazines; Quinolines; Signal Transduction; Tetradecanoylphorbol Acetate; Transcription Factor AP-1; Transcription Factor RelA; Tumor Necrosis Factor-alpha; U937 Cells; Uridine | 2000 |
Inhibitory effects of vesnarinone on cloned cardiac delayed rectifier K(+) channels expressed in a mammalian cell line.
Topics: Action Potentials; Cation Transport Proteins; Cell Line; DNA-Binding Proteins; Dose-Response Relationship, Drug; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Heart; Humans; Phosphodiesterase Inhibitors; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Pyrazines; Quinolines; Recombinant Proteins; Time Factors; Trans-Activators; Transcriptional Regulator ERG | 2000 |
Estrogen is associated with improved survival in aging women with congestive heart failure: analysis of the vesnarinone studies.
Topics: Aged; Cardiotonic Agents; Estradiol Congeners; Estrogen Replacement Therapy; Female; Heart Failure; Humans; Middle Aged; Multicenter Studies as Topic; Pyrazines; Quinolines; Randomized Controlled Trials as Topic; Survival Analysis | 2000 |
Pimobendan inhibits the activation of transcription factor NF-kappaB: a mechanism which explains its inhibition of cytokine production and inducible nitric oxide synthase.
Topics: Amrinone; Animals; Cardiotonic Agents; Colforsin; Cytokines; Humans; Interleukin-1; Luciferases; Macrophages; Mice; NF-kappa B; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Phosphodiesterase Inhibitors; Pyrazines; Pyridazines; Quinolines; Tetradecanoylphorbol Acetate; Transfection; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2000 |
Vesnarinone restores contractility and calcium handling in early endotoxemia.
Topics: Animals; Calcium; Cardiac Pacing, Artificial; Cardiotonic Agents; Disease Models, Animal; Endotoxemia; Fluorescent Dyes; Heterocyclic Compounds, 3-Ring; In Vitro Techniques; Infusions, Intravenous; Intracellular Fluid; Lipopolysaccharides; Myocardial Contraction; Oxygen Consumption; Pyrazines; Quinolines; Rabbits; Ventricular Function, Left | 2000 |
Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST).
Topics: Adult; Age Distribution; Age Factors; Aged; Aged, 80 and over; Antigens, CD; Biomarkers; Cardiotonic Agents; Clinical Trials as Topic; Cohort Studies; Cytokines; Demography; Female; Heart Failure; Humans; Interleukin-6; Male; Middle Aged; Multicenter Studies as Topic; Predictive Value of Tests; Pyrazines; Quinolines; Receptors, Cytokine; Receptors, Interleukin-6; Receptors, Tumor Necrosis Factor; Receptors, Tumor Necrosis Factor, Type I; Receptors, Tumor Necrosis Factor, Type II; Severity of Illness Index; Sex Distribution; Sex Factors; Survival Analysis; Tumor Necrosis Factor-alpha | 2001 |
OPC-8212, a quinoline derivative, counteracts the reduction in type III collagen mRNA due to lipopolysaccharides in cultured rat cardiac fibroblasts.
Topics: Animals; Cardiotonic Agents; Collagen; Enzyme-Linked Immunosorbent Assay; Fibroblasts; In Vitro Techniques; Lipopolysaccharides; Myocardial Contraction; Myocardium; Pyrazines; Quinolines; Rats; Rats, Sprague-Dawley; RNA, Messenger; Stimulation, Chemical; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha | 2001 |
Open channel block of HERG K(+) channels by vesnarinone.
Topics: Alanine; Amino Acid Sequence; Animals; Binding Sites; Cardiotonic Agents; Cation Transport Proteins; DNA-Binding Proteins; Electrophysiology; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; KCNQ Potassium Channels; KCNQ1 Potassium Channel; Molecular Sequence Data; Mutagenesis, Site-Directed; Oocytes; Patch-Clamp Techniques; Potassium Channels; Potassium Channels, Voltage-Gated; Protein Conformation; Pyrazines; Quinolines; Sequence Homology, Amino Acid; Time Factors; Trans-Activators; Transcriptional Regulator ERG; Xenopus laevis | 2001 |
Interferon-alpha 2b and vesnarinone influence levels of tumor necrosis factor-alpha, apoptosis, or interleukin 6 in ESKOL, a hairy cell leukemic cell line. A potential cytokine and oncogene relationship regulating apoptosis is suggested.
Topics: Antigens, Nuclear; Antineoplastic Agents; Apoptosis; Gene Expression Regulation, Leukemic; Genes, bcl-2; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-6; Leukemia, Hairy Cell; Nuclear Proteins; Oncogenes; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Quinolines; Recombinant Proteins; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2002 |
Item response models for joint analysis of quality of life and survival.
Topics: Area Under Curve; Cardiotonic Agents; Clinical Trials as Topic; Computer Simulation; Heart Failure; Humans; Markov Chains; Models, Biological; Monte Carlo Method; Proportional Hazards Models; Pyrazines; Quality of Life; Quinolines; Surveys and Questionnaires; Survival Analysis | 2002 |
Vesnarinone causes oxidative damage by inhibiting catalase function through ceramide action in myeloid cell apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Catalase; Cell Division; Ceramides; Drug Synergism; Enzyme Inhibitors; HL-60 Cells; Humans; Lipid Peroxidation; Oxidative Stress; Pyrazines; Quinolines; Sphingosine | 2002 |
Inotropic agents and immune modulation.
Topics: Adjuvants, Immunologic; Animals; Cardiotonic Agents; Clinical Trials as Topic; Cytokines; Heart Failure; Humans; Myocardium; Phosphodiesterase Inhibitors; Pyrazines; Pyridazines; Quality of Life; Quinolines; Time Factors | 2002 |
Vesnarinone, a differentiation inducing drug, directly activates p21(waf1) gene promoter via Sp1 sites in a human salivary gland cancer cell line.
Topics: Antineoplastic Agents; Cell Differentiation; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Electrophoretic Mobility Shift Assay; Gene Deletion; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Histone Deacetylases; Humans; Luciferases; Plasmids; Promoter Regions, Genetic; Pyrazines; Quinolines; Salivary Gland Neoplasms; Sp1 Transcription Factor; Transcription, Genetic; Transcriptional Activation; Tumor Cells, Cultured; Up-Regulation | 2002 |
Voltage-dependent profile of human ether-a-go-go-related gene channel block is influenced by a single residue in the S6 transmembrane domain.
Topics: Binding Sites; Cation Transport Proteins; DNA-Binding Proteins; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Membrane Proteins; Phosphodiesterase Inhibitors; Point Mutation; Potassium Channels; Potassium Channels, Voltage-Gated; Protein Structure, Tertiary; Pyrazines; Quinidine; Quinine; Quinolines; Trans-Activators; Transcriptional Regulator ERG; Tyrosine | 2003 |
Transcriptional activation of cyclin-dependent kinase inhibitor, p21waf1 gene by treatment with a differentiation inducing agent, vesnarinone in a human salivary gland cancer cell line.
Topics: Antineoplastic Agents; Cell Differentiation; Cell Division; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinases; Cyclins; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Plasmids; Pyrazines; Quinolines; RNA, Messenger; Salivary Gland Neoplasms; Transcriptional Activation; Tumor Cells, Cultured | 2003 |
Extended application of an LC-MS/MS method for the analysis of vesnarinone and its metabolites in human urine and dialysate fluid.
Topics: Dialysis Solutions; Gas Chromatography-Mass Spectrometry; Humans; Pyrazines; Quinolines | 2003 |
HARRY Samuel Arkin, 1893-1951.
Topics: History, 19th Century; History, 20th Century; Pyrazines; Quinolines | 1952 |
Comparison of kinetic properties of quinidine and dofetilide block of HERG channels.
Topics: Animals; Dose-Response Relationship, Drug; Electrophysiology; Gene Expression; Humans; Japan; Membrane Potentials; Oocytes; Patch-Clamp Techniques; Phenethylamines; Potassium Channels, Voltage-Gated; Pyrazines; Quinidine; Quinolines; Sulfonamides; Time Factors; Xenopus laevis | 2004 |
The best of times, the worst of times: the wealth and poverty of heart failure pharmacotherapies: is there a role for vesnarinone?
Topics: Clinical Trials as Topic; Drug Therapy; Forecasting; Heart Failure; Humans; Pyrazines; Quinolines; Quinolones; Socioeconomic Factors; Time Factors | 2004 |
A comparison of the covalent binding of clozapine, procainamide, and vesnarinone to human neutrophils in vitro and rat tissues in vitro and in vivo.
Topics: Animals; Bone Marrow; Clozapine; Female; Hemocyanins; Humans; Immune Sera; Molecular Structure; Molecular Weight; Neutrophils; Phorbol Esters; Procainamide; Pyrazines; Quinolines; Rats; Temperature | 2005 |
Vesnarinone inhibits angiogenesis and tumorigenicity of human oral squamous cell carcinoma cells by suppressing the expression of vascular endothelial growth factor and interleukin-8.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Interleukin-8; Mice; Mice, Inbred BALB C; Mice, Nude; Mouth Neoplasms; Neovascularization, Pathologic; NF-kappa B; Protein Binding; Pyrazines; Quinolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2005 |
Placebo effect-adjusted assessment of quality of life in placebo-controlled clinical trials.
Topics: Algorithms; Biometry; Cardiotonic Agents; Clinical Trials, Phase III as Topic; Controlled Clinical Trials as Topic; Endpoint Determination; Heart Failure; Humans; Likelihood Functions; Models, Statistical; Monte Carlo Method; Multicenter Studies as Topic; Placebo Effect; Pyrazines; Quality of Life; Quinolines; Randomized Controlled Trials as Topic | 2008 |
Vesnarinone represses the fibrotic changes in murine lung injury induced by bleomycin.
Topics: Animals; Bleomycin; Bronchoalveolar Lavage Fluid; Cytokines; Diet; Hyaluronic Acid; Hydroxyproline; Lung; Male; Mice; Mice, Inbred ICR; Pulmonary Fibrosis; Pyrazines; Quinolines; Receptors, Tumor Necrosis Factor; Severity of Illness Index | 2009 |
Vesnarinone downregulates CXCR4 expression via upregulation of Krüppel-like factor 2 in oral cancer cells.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cisplatin; Down-Regulation; Flow Cytometry; Fluorouracil; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Kruppel-Like Transcription Factors; Luciferases; Mice; Mice, Inbred BALB C; Mice, Nude; Mouth Neoplasms; Oligonucleotide Array Sequence Analysis; Promoter Regions, Genetic; Pyrazines; Quinolines; Receptors, CXCR4; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Tumor Burden; Xenograft Model Antitumor Assays | 2009 |
Vesnarinone suppresses TNFα mRNA expression by inhibiting valosin-containing protein.
Topics: Adenosine Triphosphatases; Cell Cycle Proteins; Cell Line; HEK293 Cells; Humans; I-kappa B Proteins; NF-kappa B; NF-KappaB Inhibitor alpha; Proteasome Endopeptidase Complex; Pyrazines; Quinolines; RNA, Messenger; Tumor Necrosis Factor-alpha; Valosin Containing Protein | 2013 |
Structural investigation of vesnarinone at the pore domains of open and open-inactivated states of hERG1 K
Topics: Arrhythmias, Cardiac; ERG1 Potassium Channel; Humans; Molecular Docking Simulation; Molecular Dynamics Simulation; Potassium Channel Blockers; Protein Conformation; Pyrazines; Quinolines | 2017 |